Hi, Tracy, Welcome. I'm Valerie Bowling. I'm the executive director over at the Conference Forum, and I'm with Tracy Kimball, who is the director of DEFARM, and we are delighted to bring forward information about a particular section of the conference called Pharma from the Trenches. So DEFARM, which stands for Disruptive Innovations to Modernize Clinical Trials, is happening September
sixteenth and seventeenth in Philadelphia at the Loew's Hotel. And I'm happy to say that we have the whole hotel this year because we have to accommodate I think just over now a thousand people. Having said that, we are doing a series and like little vignettes on covering different aspects of the conference. This is a celebration year of bringing innovation. Well, in this case, it's really going to be from the trenches, which is the theme of this
particular podcast. But what is DEFARM about. Really, It's about, in its simplest form, how can we disrupt the way we do clinical research to make trials more efficient, more accessible, more inclusive, less expensive, and ultimately far more patient centric and hopefully site centric. Right, So those are the goals that DEFARM has when every year has to raise the bar to reach those goals. And our job is to
report on innovation. What are people doing that they're really proud of that's been working for them, that they can share with industry, and that's that's what we bring forward
at DEFARM. So if you all remember David Letterman's Top ten list, I'm going to ask Tracy and challenge Tracy to give us the sixteen sessions really short, like thirty seconds or less, on what's happening with Fharma from the Trenches, which is always featured on day one, in this case September sixteenth, and it features sixteen sessions on representing companies all pharma on something they're doing very special that they want to share to help people in clinical trial operations.
So I'm setting up the scene for folks, and Trey going to hand it over to you to go through the sixteen sessions really really briefly, like what's the company and what are they going to deliver our share? So we're going to start with number sixteen and go for it. And by the way, folks, this is not like with David Letterman's Top ten, like the number one is like whatever. The most outrageous. This is not that this is just
sixteen and there's nothing in particular order. It's just we have sixteen of them, So go ahead, Tracy, to take it away.
We have Amgen reporting on their custom built AI tool to advance clinical trial operations. Mind Men on their use of large language models for reader oversight in clinical trials for efficiency and quality. Pfizer on an evaluation framework for using Genitor AI safety and quality focus, gen Map on a homegrown AI tool that accelerates safety surveillance.
Right, that's our first four.
We have Roach looking at their process for optimizing protocol and ements across the portfolio. Vertex reporting on predictive analytics and gen AI solutions in clinical trial operations and update to their twenty twenty three presentation. Gilead on the use of AI and designing, planning and monitoring the performance of
clinical trials at scale. Moderna on its framework for end to end planning and forecasting really focused on breaking down silos and streamlining operations across clinical trial operations.
Okay, so that's our second four. Okay, eight down, eight to go go for it. Buysor on its next generation EDC.
SLASH CDMs platform that they're co developing with a tool provider, Santafie on leveraging EHR data at scale to speed patient recruitment. Findser on scaling DCT adoption XUS globally, Daichi Sankyo on its homegrown clinical operations dash forward and metrics.
Okay, so I think we got four more to go.
Regeneron on its use of AI and surveys and to call public and private data for patient insights to use those in clinical trial design, Booking your angle time on its process for rethinking change management to accelerate innovation adoption at sites bias. Then on a novel screening ID mechanisms it's home grown to drive patient recruitment. And here on its proactive engagement strategies for driving future adoption of digital biomarkers.
All right, nice, So that's our sixteen sessions for Farmer from the Trenches, Tracy, Thanks so much again. Defarm September sixteenth and seventeenth in Philadelphia, And to get more information, just visit our website and at the conferenceform dot org, or you could go right to I think it's defarmconference dot com. All right, thank you so much